Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methylprednisolone + upadacitinib
- Development stage
- Preclinical
- Lead developer
- AbbVie
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Intramuscular, Topical
01
Overview
A combination of methylprednisolone, a synthetic glucocorticoid corticosteroid, and upadacitinib (RINVOQ), a selective JAK1 inhibitor. This combination may have enhanced anti-inflammatory effects but also potentially increased immunosuppressive risks. Methylprednisolone acts through glucocorticoid receptor binding to reduce inflammation, while upadacitinib selectively inhibits JAK1 signaling to block inflammatory cytokine pathways.
02
Targets
GR (Glucocorticoid receptor)JAK1 (Janus kinase 1)
Beyond the preview
Go deeper on methylprednisolone + upadacitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methylprednisolone + upadacitinib.